Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biodesign Otologic Graft in Tympanoplasty
NCT03904316Phase 4Withdrawn
- Sponsor
- Henry Ford Health
- Start
- Oct 2018
- Primary completion
- Jul 2022
- Countries
- 1
01
Overview
Phase 4, randomised trial in tympanic membrane perforation (2 arms), sponsored by Henry Ford Health. Primary endpoint: Assessment of graft take after tympanoplasty at 6 months. Planned start Oct 2018; status: withdrawn.
02
Conditions
tympanic membrane perforation
Beyond the preview
Go deeper on NCT03904316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03904316.